Novocure has 2020 prelims, update at JPM

 Full year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019

Novocure to present at the 39th Annual J.P. Morgan Virtual Healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021

Fourth quarter and full year 2020 financial results to be reported Thursday, Feb. 25, 2021

At December 31, 2020, on a preliminary, unaudited basis, Novocure had $235 million in cash and cash equivalents and $608 million in short-term investments, for a total balance of $843 million in cash, cash equivalents and short-term investments. This represents an increase of $608 million in cash and investments since September 30, 2020.

Anticipated clinical milestones

• Data from phase 2 pilot HEPANOVA trial in advanced liver cancer (Q1 2021)
• Data from phase 2 pilot EF-31 trial in gastric cancer (2021)
• Interim analysis of phase 3 pivotal LUNAR trial in non-small cell lung cancer (2021)
• Interim analysis of phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2021)
• Interim analysis of phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (2021)
• Data from phase 3 pivotal METIS trial in brain metastases (2022)
• Data from phase 2 pilot EF-33 trial with high-intensity arrays in recurrent glioblastoma (2022)
• Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2023)
• Final data from phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2023)
• Final data from phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (2023)

https://www.businesswire.com/news/home/20210111005442/en/Novocure-Announces-Fourth-Quarter-and-Full-Year-2020-Preliminary-Net-Revenues-and-Provides-Company-Update